Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Autor: | Vivek K. Kashyap, Nirnoy Dan, Murali M. Yallapu, Saini Setua, Subhash C. Chauhan, Meena Jaggi, Sheema Khan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Drug drug conjugation and cancer therapy media_common.quotation_subject medicine.medical_treatment Cancer therapy Pharmaceutical Science lcsh:Medicine lcsh:RS1-441 Review lcsh:Pharmacy and materia medica 03 medical and health sciences 0302 clinical medicine antibody Drug Discovery medicine Cytotoxic T cell media_common Chemotherapy biology Chemistry chemical linker lcsh:R 3. Good health body regions 030104 developmental biology 030220 oncology & carcinogenesis Drug delivery drug delivery biology.protein Cancer research Molecular Medicine Antibody Linker Conjugate |
Zdroj: | Pharmaceuticals, Vol 11, Iss 2, p 32 (2018) Pharmaceuticals |
ISSN: | 1424-8247 |
Popis: | Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |